ArticleDiscover oncology2026
miR-155-5p promotes osteosarcoma progression and cisplatin resistance by targeting the SOCS1/STAT1/c-Fos signaling axis.
Article in Discover oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
BACKGROUND AND
aimOsteosarcoma remains challenging to treat due to metastasis and chemoresistance. This study investigated the role and mechanisms of miR-155-5p in osteosarcoma progression and chemoresistance.
methodsWe analyzed miR-155-5p expression in clinical datasets and evaluated its biological functions in osteosarcoma cell lines through proliferation, migration, and apoptosis assays. Target identification and validation were performed using bioinformatics analysis, dual-luciferase reporter assays, and molecular studies. Cisplatin-resistant cells were used to examine chemoresistance mechanisms.
resultsElevated miR-155-5p expression correlated with poor survival in patients and was significantly upregulated in osteosarcoma. miR-155-5p promoted proliferation and migration while inhibiting apoptosis across multiple cell lines. Mechanistically, miR-155-5p directly targeted SOCS1, leading to decreased STAT1 and increased c-Fos expression. This axis modulated downstream effectors including P-glycoprotein, Bcl-2, and Bax. In cisplatin-resistant cells, dysregulation of the miR-155-5p/SOCS1 axis contributed to drug resistance.
conclusionsmiR-155-5p functions as an oncogenic microRNA by targeting the SOCS1/STAT1/c-Fos axis, promoting malignant behaviors and chemoresistance in osteosarcoma. This pathway represents a potential therapeutic target.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.